Kestra medical technologies, ltd.KMTS.US Overview
KMTS Overall Performance
KMTS AI Analysis & Strategy
Browsing restrictions can be lifted for a fee.
KMTS Key Information
KMTS Financial Forecast
Browsing restrictions can be lifted for a fee.
| Quarterly | EPS Forecast | QoQ | Max | Min |
|---|---|---|---|---|
| 2025Q1 | ||||
| 2025Q2 | ||||
| 2025Q3 | ||||
| 2025Q4 | ||||
| 2026Q1 |
KMTS Earnings Table
Unit : USD
| QTR | Non-GAAP EPS | EPS YoY | EPS Surprise % | Sales | Sales YoY | Sales Surprise % | NPM |
|---|---|---|---|---|---|---|---|
| Current | |||||||
| 2024Q4 | |||||||
| 2024Q3 | |||||||
| 2024Q2 | |||||||
| 2024Q1 |
KMTS Profile
Kestra Medical Technologies, Ltd. operates as a wearable medical device and digital healthcare company. It focuses on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. The company develops and commercializes Cardiac Recovery System platform, a system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution. Its Cardiac Recovery System platform is the ASSURE WCD, a wearable cardioverter defibrillator (WCD) used to protect patients at an elevated risk of sudden cardiac arrest (SCA). The company's Cardiac Recovery System platform also includes a suite of integrated digital solutions and services that enable enhanced patient and provider engagement and oversight with the objective of improving patient outcomes. The company was founded in 2014 and is based in Kirkland, Washington.
Price of KMTS
KMTS FAQ
When is KMTS's latest earnings report released?
The most recent financial report for Kestra medical technologies, ltd. (KMTS) covers the period of 2026Q2 and was published on 2025/10/31. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating KMTS's short-term business performance and financial health. For the latest updates on KMTS's earnings releases, visit this page regularly.
What is the operating profit of KMTS?
According to the latest financial report, Kestra medical technologies, ltd. (KMTS) reported an Operating Profit of -31.76M with an Operating Margin of -140.73% this period, representing a decline of 65.96% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.
How is KMTS's revenue growth?
In the latest financial report, Kestra medical technologies, ltd. (KMTS) announced revenue of 22.57M, with a Year-Over-Year growth rate of 53.4%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.
How much debt does KMTS have?
As of the end of the reporting period, Kestra medical technologies, ltd. (KMTS) had total debt of 44.8M, with a debt ratio of 0.18. Long-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.
How much cash does KMTS have?
At the end of the period, Kestra medical technologies, ltd. (KMTS) held Total Cash and Cash Equivalents of 177.62M, accounting for 0.72 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.
Does KMTS go with three margins increasing?
In the latest report, Kestra medical technologies, ltd. (KMTS) did not achieve the “three margins increasing” benchmark, with a gross margin of 50.6%%, operating margin of -140.73%%, and net margin of -145.3%%. This demonstrates limited improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess KMTS's profit trajectory and future growth potential.
Is KMTS's EPS continuing to grow?
According to the past four quarterly reports, Kestra medical technologies, ltd. (KMTS)'s earnings per share (EPS) shows a declining trend, with the latest EPS at -0.64. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.
What is the FCF of KMTS?
Kestra medical technologies, ltd. (KMTS)'s Free Cash Flow (FCF) for the period is -25.76M, calculated as Operating Cash Flow minus Capital Expenditures, representing a fall of 14.74% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.
What are the PEG ratio and PE ratio of KMTS?
The latest valuation data shows Kestra medical technologies, ltd. (KMTS) has a Price-To-Earnings (PE) ratio of -10.47 and a Price/Earnings-To-Growth (PEG) ratio of -0.38. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.